Anika Total Other Income Expense Net vs Gross Profit Analysis
ANIK Stock | USD 16.23 0.08 0.49% |
Anika Therapeutics financial indicator trend analysis is way more than just evaluating Anika Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Anika Therapeutics is a good investment. Please check the relationship between Anika Therapeutics Total Other Income Expense Net and its Gross Profit accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
Total Other Income Expense Net vs Gross Profit
Total Other Income Expense Net vs Gross Profit Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Anika Therapeutics Total Other Income Expense Net account and Gross Profit. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Anika Therapeutics' Total Other Income Expense Net and Gross Profit is 0.59. Overlapping area represents the amount of variation of Total Other Income Expense Net that can explain the historical movement of Gross Profit in the same time period over historical financial statements of Anika Therapeutics, assuming nothing else is changed. The correlation between historical values of Anika Therapeutics' Total Other Income Expense Net and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Other Income Expense Net of Anika Therapeutics are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Total Other Income Expense Net i.e., Anika Therapeutics' Total Other Income Expense Net and Gross Profit go up and down completely randomly.
Correlation Coefficient | 0.59 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Total Other Income Expense Net
Gross Profit
Gross profit is a required income statement account that reflects total revenue of Anika Therapeutics minus its cost of goods sold. It is profit before Anika Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most indicators from Anika Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Anika Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.At this time, Anika Therapeutics' Selling General Administrative is quite stable compared to the past year. Enterprise Value is expected to rise to about 537.5 M this year, although the value of Tax Provision is projected to rise to (3.7 M).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 82.9M | 93.6M | 103.1M | 108.2M | Total Revenue | 147.8M | 156.2M | 166.7M | 175.0M |
Anika Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Anika Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Anika Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 330.7M | 365.6M | 347.5M | 349.1M | 270.6M | 148.0M | |
Other Current Liab | 11.3M | 26.3M | 20.4M | 16.0M | 17.8M | 18.7M | |
Total Current Liabilities | 16.3M | 36.9M | 29.8M | 27.9M | 31.1M | 32.6M | |
Total Stockholder Equity | 288.4M | 272.4M | 287.1M | 285.6M | 212.3M | 120.9M | |
Property Plant And Equipment Net | 73.6M | 73.2M | 68.6M | 79.0M | 75.0M | 78.7M | |
Net Debt | (136.1M) | (74.9M) | (75.1M) | (55.4M) | (43.8M) | (46.0M) | |
Retained Earnings | 245.4M | 221.4M | 225.6M | 210.7M | 128.1M | 71.7M | |
Accounts Payable | 3.8M | 9.0M | 7.6M | 9.1M | 9.9M | 10.4M | |
Cash | 157.5M | 95.8M | 94.4M | 86.3M | 72.9M | 54.9M | |
Non Current Assets Total | 96.4M | 188.2M | 179.0M | 179.6M | 107.3M | 55.4M | |
Cash And Short Term Investments | 184.9M | 98.3M | 94.4M | 86.3M | 72.9M | 62.2M | |
Net Receivables | 23.1M | 24.1M | 29.8M | 34.6M | 36.0M | 37.8M | |
Common Stock Shares Outstanding | 14.4M | 14.2M | 14.6M | 14.6M | 14.7M | 12.7M | |
Liabilities And Stockholders Equity | 330.7M | 365.6M | 347.5M | 349.1M | 270.6M | 148.0M | |
Non Current Liabilities Total | 26.1M | 56.3M | 30.7M | 35.7M | 27.3M | 15.3M | |
Inventory | 22.0M | 46.2M | 36.0M | 39.8M | 46.4M | 48.7M | |
Other Current Assets | 1.4M | 8.8M | 16.6M | 17.7M | 8.1M | 8.5M | |
Other Stockholder Equity | 48.7M | 55.4M | 67.1M | 81.1M | 90.0M | 54.8M | |
Total Liab | 42.3M | 93.2M | 60.5M | 63.6M | 58.4M | 61.3M | |
Property Plant And Equipment Gross | 73.6M | 73.2M | 47.6M | 48.3M | 122.6M | 128.8M | |
Total Current Assets | 235.7M | 177.4M | 168.5M | 169.5M | 163.3M | 92.6M | |
Accumulated Other Comprehensive Income | (5.9M) | (4.5M) | (5.7M) | (6.4M) | (5.9M) | (6.2M) | |
Non Currrent Assets Other | 7.5M | 15.4M | 20.3M | 17.2M | 18.7M | 19.6M | |
Common Stock Total Equity | 147K | 142K | 143K | 144K | 167.9K | 139.2K | |
Short Term Investments | 70.0M | 27.5M | 2.5M | 34.6M | 39.8M | 41.8M | |
Other Assets | (1.4M) | 38.0M | 20.3M | 18.7M | 21.5M | 22.5M | |
Property Plant Equipment | 50.8M | 50.6M | 47.6M | 48.3M | 55.5M | 32.3M | |
Other Liab | 4.7M | 35.5M | 11.4M | 6.8M | 6.2M | 8.1M | |
Good Will | 7.7M | 8.4M | 7.8M | 7.3M | 7.6M | 8.0M | |
Intangible Assets | 7.6M | 91.2M | 82.4M | 74.6M | 4.6M | 4.4M | |
Net Tangible Assets | 294.5M | 193.7M | 216.2M | 232.4M | 267.3M | 227.7M | |
Retained Earnings Total Equity | 245.4M | 221.4M | 225.6M | 210.7M | 242.3M | 149.3M | |
Capital Surpluse | 48.7M | 55.4M | 67.1M | 81.1M | 73.0M | 52.5M | |
Deferred Long Term Liab | 4.3M | 11.9M | 10.2M | 6.4M | 7.4M | 7.2M | |
Non Current Liabilities Other | 357K | 23.6M | 1.3M | 398K | 404K | 383.8K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (6.64) | Revenue Per Share 11.139 | Quarterly Revenue Growth (0.07) | Return On Assets (0.04) |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.